Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice.
Most chemical carcinogens require metabolic activation to electrophilic metabolites that are capable of binding to DNA and causing gene mutations. Carcinogen metabolism is carried out by large groups of xenobiotic-metabolizing enzymes that include the phase I cytochromes P450 (P450) and microsomal epoxide hydrolase, and various phase II transferase enzymes. It is extremely important to determine the role P450s play in the carcinogenesis and to establish if they are the rate limiting and critical interface between the chemical and its biological activities. The latter is essential in order to validate the use of rodent models to test safety of chemicals in humans. Since there are marked species differences in expressions and catalytic activities of the multiple P450 forms that activate carcinogens, this validation process becomes especially difficult. To address the role of P450s in whole animal carcinogenesis, mice were produced that lack the P450s known to catalyze carcinogen activation. Mouse lines having disrupted genes encoding the P450s CYP1A2, CYP2E1, and CYP1B1 were developed. Mice lacking expression of microsomal epoxide hydrolase (mEH) and NADPH-quinone oxidoreductase (NQO1) were also made. All of these mice exhibit no gross abnormal phenotypes, suggesting that the xenobiotic-metabolizing enzymes have no critical roles in mammalian development and physiological homeostasis. This explains the occurrence of polymorphisms in xenobiotic-metabolizing enzymes among humans and other mammalian species. However, these null mice do show differences in sensitivities to acute chemical toxicities, thus establishing the importance of xenobiotic metabolism in activation pathways that lead to cell death. Rodent bioassays using null mice and known genotoxic carcinogens should establish whether these enzymes are required for carcinogenesis in an intact animal model. These studies will also provide a framework for the production of transgenic mice and carcinogen bioassay protocols that may be more predictive for identifying the human carcinogens and validate the molecular epidemiological studies ongoing in humans that seek to establish a role for polymorphisms in cancer risk.
Gonzalez
F J
FJ
National Institutes of Health, National Cancer Institute, Building 37 Room 3E-24, Bethesda, MD 20892, USA. fjgonz@helix.nih.gov
Kimura
S
S
D000082:Acetaminophen / Q000633:toxicity; D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases; D001551:Benz(a)Anthracenes / Q000633:toxicity; D001554:Benzene / Q000633:toxicity; D002273:Carcinogens / Q000378:metabolism / Q000633:toxicity*; D065633:Cytochrome P-450 CYP1B1; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004851:Epoxide Hydrolases / Q000378:metabolism; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009369:Neoplasms / Q000139:chemically induced* / Q000201:enzymology; D015262:Xenobiotics / Q000378:metabolism / Q000633:toxicity*
D001551:Benz(a)Anthracenes; D002273:Carcinogens; D015262:Xenobiotics; C046810:7,12-dihydroxymethylbenz(a)anthracene; D000082:Acetaminophen; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; C585496:CYP1B1 protein, human; C585498:Cyp1b1 protein, mouse; D065633:Cytochrome P-450 CYP1B1; D004851:Epoxide Hydrolases; D001554:Benzene